Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

This study has been completed.
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: April 19, 2006
Last updated: September 19, 2013
Last verified: December 2007
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: February 2011
  Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)